Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease

Paul Mead, MD; Jeannine Petersen, PhD; Alison Hinckley, PhD

Disclosures

Morbidity and Mortality Weekly Report. 2019;68(32):703 

In This Article

Abstract and Introduction

Introduction

Lyme disease is a tickborne zoonosis for which serologic testing is the principal means of laboratory diagnosis. In 1994, the Association of State and Territorial Public Health Laboratory Directors, CDC, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Council of State and Territorial Epidemiologists, and the National Committee for Clinical Laboratory Standards convened the Second National Conference on Serologic Diagnosis of Lyme Disease.[1]

The conference proceedings recommended a two-test methodology using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay as a first test, followed by a western immunoblot assay for specimens yielding positive or equivocal results.[1,2] Regarding the development of future tests, the report advised that evaluation of new serologic assays include blind testing against a comprehensive challenge panel, and that new assays should only be recommended if their specificity, sensitivity, and precision equaled or surpassed the performance of tests used in the recommended two-test procedure. To assist serologic test developers, CDC has made available, with support from NIH, a comprehensive panel of sera from patients with various stages of Lyme disease and other conditions, as well as healthy persons.[3]

On July 29, 2019, FDA cleared several Lyme disease serologic assays with new indications for use based on a modified two-test methodology.[4] The modified methodology uses a second EIA in place of a western immunoblot assay. Clearance by FDA of the new Lyme disease assays indicates that test performance has been evaluated and is "substantially equivalent to or better than" a legally marketed predicate test.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....